Gene

FGFR3

fibroblast growth factor receptor 3

Explore in graph →CI-GENE-00001926HGNC:3690 ENSG00000068078 NCBI 2261 CIViC Cancer geneApproved

Curated evidence

Clinical evidence (214)

CIViC items involving this gene, grouped by molecular profile and therapy, with native levels and directions. 50 items per page.

civicCuratedShowing 51–100 of 214 evidence items · levels, directions and significance as curated at the source; each row links to its CIViC record.

Therapy	Cancer	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
FGFR3 G697C3
(oncogenic)	Malignant NeoplasmALIAS	Oncogenic	D	Does Not Support Oncogenicity	3	accepted

Cohorts

Alteration frequency by cohort (100)

Frequency = cases affected / cases profiled within one cohort. Cohorts are never pooled.

cbioportalObserved100 cohort rows (showing 50, sorted by frequency) · frequency = affected / profiled, as published by each cohort; cohorts are not pooled. Hover a row badge for its release.

Cohort	Mapped cancer	Alteration	Affected (n)	Profiled (n)	Frequency (%)	Rank in cohort	Source
Bladder Cancer (MSK, Clin Cancer Res 2023) bladder_msk_2023	unmapped	Ssm	443	526

Literature

Linked publications (36)

25 per page, newest first.

pubmedPublishedShowing 1–25 of 36 publications · bibliographic data as recorded by PubMed; abstracts are not reproduced.

Erdafitinib in Locally Advanced or Metastatic Urothelial Carcinoma.
· N Engl J Med · 2019 · PMID 31340094 · validated civic_curation pubmed
FGFR3 mutational status and protein expression in patients with bladder cancer in a Jordanian population.
· Cancer Epidemiol · 2010 · PMID 20542753 · validated civic_curation pubmed
Evaluation of BGJ398, a Fibroblast Growth Factor Receptor 1-3 Kinase Inhibitor, in Patients With Advanced Solid Tumors Harboring Genetic Alterations in Fibroblast Growth Factor Receptors: Results of a Global Phase I, Dose-Escalation and Dose-Expansion Study.
· J Clin Oncol · 2017 · PMID 27870574 · validated civic_curation pubmed
Somatic FGFR3 Mutations Distinguish a Subgroup of Muscle-Invasive Bladder Cancers with Response to Neoadjuvant Chemotherapy.
· EBioMedicine · 2018 · PMID 29941343

FGFR3 G802_X807del + FGFR3 Fusion1
Erdafitinib	Multiple Myeloma	Predictive	C	Supports Sensitivity Response	2	submitted	EID11033 Analysis of a single patient is reported from a phase II trial (NCT02952573) testing erdafitinib in relapsed/refractory myeloma patients with or without FGFR3 mutations. The single patient (52 year ol… (full text at CIViC) PMID 36639200 · Croucher et al., 2023 · Open in CIViC	civic

FGFR3 G802_X807del + FGFR3 Fusion1

Erdafitinib

Multiple Myeloma

Predictive

Supports Sensitivity Response

submitted

EID11033

Analysis of a single patient is reported from a phase II trial (NCT02952573) testing erdafitinib in relapsed/refractory myeloma patients with or without FGFR3 mutations. The single patient (52 year ol… (full text at CIViC)

PMID 36639200 · Croucher et al., 2023 · Open in CIViC

FGFR3 K508M12
(functional)	—UNRESOLVED	Functional	D	Supports Loss Of Function	2	submitted	EID11796 This study used micropatterned surfaces to enrich fluorophore-tagged FGFR3 in specific areas of the plasma membrane. Researchers quantified receptor activation by capturing cellular activity using tot… (full text at CIViC) PMID 36581204 · Hartl et al., 2023 · Open in CIViC	civic
(oncogenic)	Malignant Nasopharyngeal NeoplasmALIAS	Oncogenic	D	Does Not Support Oncogenicity	2	submitted	EID11797 Paper analysing FGFR3-TACC3 frequency and oncogenicity in nasopharyngeal carcinoma. FGFR3-TACC3-K508M in HNE1 and HK1 NPC cell lines showed a significant reduction of cellular proliferation in the col… (full text at CIViC) PMID 25535896 · Yuan et al., 2014 · Open in CIViC	civic
〃	Pancreatic Ductal Adenocarcinoma	Oncogenic	D	Does Not Support Oncogenicity	2	submitted	EID11798 The study analysed the expression of the two splice variants of FGFR3 (FGFR3-IIIb and FGFR3-IIIc/FGFR3-IIIc-KD) in two pancreatic ductal adenocarcinoma cell lines (Capan-2 and BxPC-3). The FGFR3-IIIc-… (full text at CIViC) PMID 23902722 · Lafitte et al., 2013 · Open in CIViC	civic
〃	Malignant Cervical Neoplasm	Oncogenic	D	Does Not Support Oncogenicity	2	submitted	EID11799 A study that aims to analyse the biological significance of the FGFR3-TACC3 fusion. They transfected the K508M (also referred to as KD or kinase-dead) FGFR3-TACC3 fusion transcript into cervical epith… (full text at CIViC) PMID 29358619 · Tamura et al., 2018 · Open in CIViC	civic
〃	Malignant NeoplasmALIAS	Oncogenic	D	Does Not Support Oncogenicity	2	submitted	EID11800 cDNAs encoding wild-type FGFR3 and other variants such as the kinse dead K508M (F3-B-KD) were inserted into the pCXND3 vector and used to transfect cells. No phosphorylation of the K508M variant was d… (full text at CIViC) PMID 25589496 · Nakanishi et al., 2015 · Open in CIViC	civic
〃	Malignant NeoplasmALIAS	Oncogenic	D	Does Not Support Oncogenicity	2	submitted	EID11802 Study show that the FGFR3-TACC3 (F3-T3) fusion triggers peroxisome biogenesis and new protein synthesis, enabling mitochondrial respiration and tumor growth. They expressed F3-T3 fusion in immortalize… (full text at CIViC) PMID 29323298 · Frattini et al., 2018 · Open in CIViC	civic
〃	Bladder Carcinoma	Oncogenic	D	Does Not Support Oncogenicity	2	submitted	EID11803 The study found that TGFβ-activated kinase 1 (TAK1) is a novel protein that interacts and is targeted by FGFR3 kinase activity. Activating mutations in FGFR3 modulate expression of genes that regulate… (full text at CIViC) PMID 24466111 · Salazar et al., 2014 · Open in CIViC	civic
〃	Multiple Myeloma	Oncogenic	D	Does Not Support Oncogenicity	2	submitted	EID11804 The study found that FGFR3 interacts with a regulatory subunit of PI3K, and this interaction negatively regulates the Ras/ERK/MAPK pathway in response to FGFR3 activity. This interaction could be a po… (full text at CIViC) PMID 19286672 · Salazar et al., 2009 · Open in CIViC	civic
〃	Malignant NeoplasmALIAS	Oncogenic	D	Does Not Support Oncogenicity	2	submitted	EID11805 Authors wanted to determine Ship2 role in FGF-mediated cell migration. They used the CRISPR/Cas9 system to disrupt the Ship2 gene in RCS cells. They found that loss of SHIP2 converted FGF-mediated sus… (full text at CIViC) PMID 30228226 · Fafilek et al., 2018 · Open in CIViC	civic
〃	GlioblastomaCURATED_BROADER	Oncogenic	D	Does Not Support Oncogenicity	2	submitted	EID11806 Rat1A astrocytes cells expressing the FGFR3-TACC3-K508M were tested to evaluate anchorage-independent growth in soft agar (Fig. 2A and table S5) and did not show an ability to grow evidenced by no col… (full text at CIViC) PMID 22837387 · Singh et al., 2012 · Open in CIViC	civic
〃	OsteochondrodysplasiaUNRESOLVED	Oncogenic	D	Does Not Support Oncogenicity	2	submitted	EID11807 A study was conducted to analyze the impact of mutations in the transmembrane and kinase domains that cause skeletal dysplasias. The study used PC12 cells with FGFR3 variants that were introduced by s… (full text at CIViC) PMID 9857065 · Raffioni et al., 1998 · Open in CIViC	civic
〃	OsteochondrodysplasiaUNRESOLVED	Oncogenic	D	Does Not Support Oncogenicity	1	submitted	EID11801 HeLa, 293T and RCS cells were transfected with N540K, G380R, R248C, Y373C, K650M, K650E and K508M to test STAT1(Y701) activation. The assay showed no activation in cells transfected with the kinase-in… (full text at CIViC) PMID 19088846 · Krejci et al., 2008 · Open in CIViC	civic

FGFR3 K650E15
(oncogenic)	Hematopoietic and Lymphoid Cell NeoplasmALIAS	Oncogenic	D	Supports Oncogenicity	4	submitted	EID10370 Authors of this paper aimed to investigate the role of the FGFR3 K650E variant in transforming cells in vivo and in vitro. After 3-4 weeks of transducing mice’s bone marrow (BM) with the mutant recept… (full text at CIViC) PMID 11290605 · Li et al., 2001 · Open in CIViC	civic
(functional)	—UNRESOLVED	Functional	D	Supports Gain Of Function	3	submitted	EID10086 25 FGFR3 mutant proteins were isolated and their auto-phosphorylation and kinase activity was measured and compared to wild-type. 6 mutations (N540K, N540S, K650E, K650N, R669G, R669Q) demonstrated in… (full text at CIViC) PMID 26992226 · Patani et al., 2016 · Open in CIViC	civic
〃	—UNRESOLVED	Functional	D	Supports Gain Of Function	3	accepted	EID10393 NIH 3T3 cells were transfected with wild-type and mutant K650E FGFR3. Immunoprecipitation measuring kinase activity showed FGFR3 K650E had 100-fold greater autophosphorylation than wildtype. The autho… (full text at CIViC) PMID 8754806 · Webster et al., 1996 · Open in CIViC	civic
〃	—UNRESOLVED	Functional	D	Supports Gain Of Function	3	accepted	EID10493 A construct of PDGF and FGFR3 was created as a chimeric receptor to study the effect of the K650E variant on downstream signaling pathways. Transfecting PC12 cells showed continuous ligand-independent… (full text at CIViC) PMID 15843401 · Nowroozi et al., 2005 · Open in CIViC	civic
〃	—UNRESOLVED	Functional	D	Supports Gain Of Function	3	submitted	EID10653 Rare germline and somatic cancer variant FGFR3 K650E crystal structure was compared to phosphorylated and unphosphorylated FGF1 and FGF2 via superimposition. This comparison showed that K650E (located… (full text at CIViC) PMID 23972473 · Huang et al., 2013 · Open in CIViC	civic
(oncogenic)	Malignant NeoplasmALIAS	Oncogenic	D	Supports Oncogenicity	3	submitted	EID12845 The tyrosine kinase domain mutation K650E was tested in a series of assays for an evaluation of oncogenicity. K650E was stably transfected into 3T3 cells along with WT controls. TAS (Transformation … (full text at CIViC) PMID 34272467 · Nakamura et al., 2021 · Open in CIViC	civic
(functional)	—UNRESOLVED	Functional	D	Supports Unaltered Function	2	submitted	EID10391 Protein co-chaperone Cdc37 is required in FGFR3 remodeling for recognition by chaperone protein Hsp90. Cdc37 must partially deactivate the kinase and present it in a particular orientation to Hsp90. A… (full text at CIViC) PMID 29478821 · Bunney et al., 2018 · Open in CIViC	civic
(oncogenic)	Malignant NeoplasmALIAS	Oncogenic	D	Supports Oncogenicity	2	submitted	EID12889 In a saturation mutagenesis study, all possible point mutations in the FGFR 1-4 kinase domain (amino acids 472-807 for FGFR3) were tested. Lentiviral plasmids were infected at MOI < 0.3 into the growt… (full text at CIViC) PMID 41361008 · Tangermann et al., 2025 · Open in CIViC	civic
(functional)	—UNRESOLVED	Functional	D	Supports Gain Of Function	1	submitted	EID10376 The Lys650Glu variant was investigated in terms of its ability to activate the receptor kinase FGFR3. Upon NIH3T3 cells transfection, the kinase assay showed a significant increase in the ligand-indep… (full text at CIViC) PMID 10053006 · Tavormina et al., 1999 · Open in CIViC	civic
〃	—UNRESOLVED	Functional	D	Supports Gain Of Function	1	accepted	EID10381 The FGFR3 variant K650E is known to be responsible for thanatophoric dysplasia type 2 (TDII), a severe form of skeletal dysplasia. The mutant receptor was tested for comparison between other variants … (full text at CIViC) PMID 11055896 · Bellus et al., 2000 · Open in CIViC	civic
(oncogenic)	Multiple Myeloma	Oncogenic	D	Supports Oncogenicity	1	submitted	EID10383 Xenografts of multiple myeloma cell line OPM2 (FGFR3 K650E) into nude mice resulted in tumor growth. PMID 19381019 · Qing et al., 2009 · Open in CIViC	civic
Midostaurin	Multiple Myeloma	Predictive	D	Supports Sensitivity Response	3	submitted	EID10407 PKC412 inhibited the growth of FGFR3 K650E-transformed Ba/F3 cells. Researchers introduced an N540D mutation to FGFR3-transformed Ba/F3 cells, which reduces inhibition of the FGFR3 K650E-transformed c… (full text at CIViC) PMID 16091734 · Chen et al., 2005 · Open in CIViC	civic
R3Mab	Multiple Myeloma	Predictive	D	Supports Sensitivity Response	4	submitted	EID10365 In culture, monoclonal antibody R3Mab treatment inhibited the growth of multiple myeloma cell line UTMC-2 which has wild type FGFR3 but did not affect proliferation of multiple myeloma cell line KMS11… (full text at CIViC) PMID 19381019 · Qing et al., 2009 · Open in CIViC	civic
〃	Malignant NeoplasmALIAS	Predictive	D	Does Not Support Resistance	3	accepted	EID10355 Ba/F3 cells transfected with wildtype FGFR3 resulted in IL-3 independence with FGF1 dependence for growth, whereas cells transfected with common bladder carcinoma variant FGFR3 K652E resulted in IL-3 … (full text at CIViC) PMID 19381019 · Qing et al., 2009 · Open in CIViC	civic
Vemurafenib	Cutaneous MelanomaALIAS	Predictive	D	Supports Resistance	—	submitted	EID4055 In an in vitro study, an A375 cell line expressing BRAF V600E (a known sensitizing mutation to vemurafenib) and FGFR3 K650E co-mutations, demonstrated resistance to vemurafenib treatment (IC50: 1480 n… (full text at CIViC) PMID 21107323 · Nazarian et al., 2010 · Open in CIViC	civic

FGFR3 K650M4
(oncogenic)	Malignant Bladder NeoplasmALIAS	Oncogenic	C	Supports Oncogenicity	1	submitted	EID10491 Targeted mutation analysis on the FGFR3 gene in 297 bladder cancer patients was conducted, where 177 patients were found to harbor FGFR3 mutations. Two patients were found to harbor the K650M variant … (full text at CIViC) PMID 12461689 · van Rhijn et al., 2002 · Open in CIViC	civic
(functional)	—UNRESOLVED	Functional	D	Supports Gain Of Function	2	submitted	EID10369 In this study, authors investigated a K650M variant in FGFR3, which occurs within the receptor tyrosine kinase domain activation loop. The variant was found in four unrelated patients, whose clinical … (full text at CIViC) PMID 10053006 · Tavormina et al., 1999 · Open in CIViC	civic
〃	—UNRESOLVED	Functional	D	Supports Gain Of Function	2	accepted	EID10380 The K650M variant in FGFR3 is known to be responsible for the severe skeletal dysplasia forms seen in thanatophoric dysplasia type 1 / severe achondroplasia with developmental delay and acanthosis nig… (full text at CIViC) PMID 11055896 · Bellus et al., 2000 · Open in CIViC	civic
(oncogenic)	Malignant NeoplasmALIAS	Oncogenic	D	Supports Oncogenicity	1	submitted	EID12890 In a saturation mutagenesis study, all possible point mutations in the FGFR 1-4 kinase domain (amino acids 472-807 for FGFR3) were tested. Lentiviral plasmids were infected at MOI < 0.3 into the growt… (full text at CIViC) PMID 41361008 · Tangermann et al., 2025 · Open in CIViC	civic